Edition:
United Kingdom

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

8.05USD
22 Feb 2018
Change (% chg)

$-0.05 (-0.62%)
Prev Close
$8.10
Open
$8.00
Day's High
$8.20
Day's Low
$7.85
Volume
60,045
Avg. Vol
137,505
52-wk High
$20.00
52-wk Low
$6.57

Chart for

About

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic... (more)

Overall

Beta: --
Market Cap(Mil.): $611.97
Shares Outstanding(Mil.): 35.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018

* CALITHERA BIOSCIENCES INC - PLAN TO INITIATE A GLOBAL, RANDOMIZED PHASE 2 TRIAL OF CB-839 IN COMBINATION WITH CABOZANTINIB IN Q2 OF 2018 Source text for Eikon: Further company coverage:

05 Feb 2018

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting

07 Nov 2017

BRIEF-Calithera Biosciences Q3 operating loss per share $0.17

* Calithera biosciences reports third quarter 2017 financial results and recent highlights

02 Nov 2017

Competitors

  Price Chg
Agios Pharmaceuticals Inc (AGIO.OQ) $81.81 +3.12
AstraZeneca plc (AZN.L) 4,772.00 -27.50
Bayer AG (BAYGn.DE) €98.44 +0.01
Bayer AG (BAYE.F) -- --
Celgene Corporation (CELG.OQ) $93.78 -0.11
Eli Lilly and Co (LLY.N) $77.19 -0.36
GlaxoSmithKline plc (GSK.L) 1,303.00 -21.60
Merck KGaA (MRCG.DE) €82.38 +0.04
Novartis AG (NOVN.S) CHF79.98 -0.22
Pfizer Inc. (PFE.N) $35.74 -0.02

Earnings vs. Estimates